Bridget Harrison, MD
Family Practice · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 5
Offices
5 locations · University Healthcare Alliance · Indian Health Center of Santa Clara Valley
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Harrison’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A104342 · Current
Licensed to practise in California · since 2008 · expires 2027-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$30,289
Medicare paid this office $30,289 for 119 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 35 | $7,195 | $111 |
| Long return visit (40+ min) | 16 | $4,651 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,338 | $101 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,449 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,318 | $155 |
See all 11 services
| Return visit (30+ min) | 35 | $7,195 | $111 |
| Long return visit (40+ min) | 16 | $4,651 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,338 | $101 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,449 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,318 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,795 | $66 |
| Sarscv2 vac 30mcg trs-suc im | 16 | $1,519 | $84 |
| Admn sarscov2 vacc 1 dose | 20 | $1,146 | $52 |
| Hospital discharge day management, 30 minutes or less | 12 | $891 | $64 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 22 | $761 | $15 |
| Hemoglobin a1c level | 18 | $93 | $5 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of nail tissue | 1-10 | None |
| Removal of skin lesions | 1-10 | None |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
119 Original Medicare patients in 2024. Average age 72 · Under 65 17% · 85 and older 13% · Women 56% · Also on Medicaid 53% · Health risk score 2.01. Above the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 75% · Diabetes 52% · Chronic kidney disease 34% · Coronary heart disease 30% · Depression 27% · Heart failure 23% · Atrial fibrillation 21% · COPD 18% · Cancer 14% · Dementia 13% · Stroke 10%.
The office billed $107,635, Medicare allowed $39,681 and paid $30,289; for 395 services of 34 kinds; $2,602 of it was for drugs given in the office and $27,687 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 119 | 395 | 72 | 2.01 | $107,635 | $30,289 |
| 2023 | 137 | 345 | 72 | 2.29 | $110,067 | $32,499 |
| 2022 | 115 | 325 | 76 | 2.13 | $109,039 | $31,845 |
| 2021 | 90 | 247 | 76 | 2.19 | $96,442 | $26,319 |
| 2020 | 89 | 165 | 75 | 2.40 | $61,794 | $15,201 |
| 2019 | 122 | 310 | 75 | 2.66 | $111,683 | $26,804 |
| 2018 | 125 | 257 | 76 | 2.63 | $92,118 | $23,214 |
| 2017 | 107 | 231 | 74 | 2.53 | $64,996 | $17,376 |
| 2016 | 37 | 66 | 71 | 1.75 | $19,114 | $5,384 |
| 2015 | 11 | 22 | 66 | 1.17 | $5,119 | $819 |
| 2014 | 56 | 95 | 66 | 1.52 | $19,952 | $3,435 |
| 2013 | 22 | 36 | 67 | 1.03 | $4,749 | $1,339 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $8,682 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,922 | $159 |
| Return visit (30+ min) | 20 | $3,501 | $109 |
| Sarscv2 vac 30mcg trs-suc im | 20 | $1,688 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,479 | $74 |
| Admn sarscov2 vacc 1 dose | 23 | $1,133 | $49 |
| Hospital discharge day management, 30 minutes or less | 12 | $964 | $74 |
| Short return visit (20+ min) | 11 | $749 | $68 |
2022: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $8,142 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,560 | $190 |
| Return visit (30+ min) | 25 | $4,521 | $108 |
| Long return visit (40+ min) | 13 | $2,866 | $169 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $2,060 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,681 | $67 |
| Hospital discharge day management, 30 minutes or less | 15 | $961 | $64 |
| Influenza vaccine split virus, preservative free | 19 | $921 | $48 |
| Administration of influenza virus vaccine | 20 | $452 | $23 |
2021: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $5,921 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,135 | $188 |
| Return visit (30+ min) | 17 | $3,671 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,600 | $62 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,086 | $64 |
2020: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $3,289 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,236 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,775 | $68 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,469 | $70 |
| Return visit (30+ min) | 13 | $1,221 | $94 |
| Short return visit (20+ min) | 11 | $650 | $59 |
2019: 7 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,765 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,561 | $93 |
| Hospital discharge day management, 30 minutes or less | 48 | $3,002 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,916 | $65 |
| Return visit (30+ min) | 17 | $2,428 | $90 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,367 | $124 |
| Short return visit (20+ min) | 15 | $1,102 | $55 |
2018: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $4,995 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,569 | $176 |
| Hospital discharge day management, 30 minutes or less | 44 | $2,919 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,252 | $119 |
| Return visit (30+ min) | 15 | $2,073 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,902 | $63 |
2017: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,757 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,539 | $122 |
| Hospital discharge day management, 30 minutes or less | 41 | $2,716 | $66 |
| Return visit (30+ min) | 16 | $2,312 | $96 |
2016: 1 service
| Return visit (30+ min) | 15 | $1,510 | $94 |
2014: 3 services
| Return visit (30+ min) | 14 | $891 | $56 |
| Short return visit (20+ min) | 18 | $634 | $32 |
| Administration of influenza virus vaccine | 13 | $405 | $31 |
2013: 1 service
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 11 | $209 | $19 |
Medicaid work
$143,566 in 2024
Medicaid paid $143,566 for 1,946 billed services this clinician did in 2024, up to 68 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 502 | $126,764 |
| Short return visit (20+ min) | 497 | $3,765 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 196 | $3,055 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 88 | $2,690 |
| Return visit (30+ min) | 198 | $1,853 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 35 | $1,819 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 93 | $1,248 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 89 | $1,149 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 25 | $318 |
| Pure tone audiometry (threshold); air only | 18 | $312 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $270 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 20 | $140 |
| 2024 | 1,946 | 15 | 68 | $143,566 |
| 2023 | 2,794 | 15 | 90 | $186,691 |
| 2022 | 1,304 | 11 | 54 | $99,951 |
| 2021 | 1,524 | 14 | 75 | $127,785 |
| 2020 | 1,716 | 11 | 150 | $147,092 |
| 2019 | 1,532 | 8 | 109 | $161,268 |
| 2018 | 2,029 | 5 | 195 | $326,972 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 666 | $157,256 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 113 | $6,905 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 62 | $4,223 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 204 | $3,442 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose | 63 | $3,419 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 89 | $2,803 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 246 | $2,713 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 185 | $1,856 |
| Short return visit (20+ min) | 644 | $1,429 |
| 1ST HOSP IP/OBS HIGH 75 | 33 | $960 |
| Return visit (30+ min) | 155 | $760 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 100 | $480 |
2022
| Clinic visit/encounter, all-inclusive | 382 | $88,362 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 90 | $6,211 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 154 | $1,575 |
| Short return visit (20+ min) | 378 | $906 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 46 | $780 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 51 | $714 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 118 | $657 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose | 13 | $335 |
| Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 16 | $280 |
| Return visit (30+ min) | 44 | $131 |
| Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month | 12 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 507 | $119,121 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 54 | $3,994 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 178 | $1,626 |
| Short return visit (20+ min) | 378 | $974 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 107 | $627 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 17 | $350 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 30 | $299 |
| Short return visit | 130 | $281 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 28 | $220 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $144 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | 12 | $105 |
| Skin test; tuberculosis, intradermal | 31 | $35 |
2020
| Clinic visit/encounter, all-inclusive | 615 | $140,011 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 287 | $2,849 |
| Short return visit (20+ min) | 539 | $1,313 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 27 | $1,141 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 87 | $531 |
| Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 13 | $520 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 20 | $358 |
| Short return visit | 71 | $191 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | 13 | $100 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 18 | $79 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 26 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 699 | $156,927 |
| Short return visit (20+ min) | 580 | $2,440 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 20 | $491 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 62 | $395 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 29 | $362 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 14 | $329 |
| Short return visit | 104 | $248 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 24 | $77 |
2018
| Clinic visit/encounter, all-inclusive | 1,212 | $270,663 |
| Short return visit (20+ min) | 741 | $54,171 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 25 | $988 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 39 | $849 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $302 |
Drugs they prescribed that Part D paid
$109,939
Pharmacies billed $109,939 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (12 of 1,019) in 2024. At or below the middle of the specialty; the typical family practice clinician is at 2%.
868 generic and 133 brand-name prescriptions · $109,939 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 34 | $41,944 | $1,234 |
| Jardiance | 13 | $10,056 | $774 |
| Albuterol Sulfate Hfa | 23 | $785 | $34 |
| Alendronate | 15 | $769 | $51 |
| Levothyroxine | 40 | $673 | $17 |
See all 22 drugs
| Ozempic | 34 | $41,944 | $1,234 |
| Jardiance | 13 | $10,056 | $774 |
| Albuterol Sulfate Hfa | 23 | $785 | $34 |
| Alendronate | 15 | $769 | $51 |
| Levothyroxine | 40 | $673 | $17 |
| Gabapentin | 36 | $627 | $17 |
| Rosuvastatin | 26 | $507 | $20 |
| Tamsulosin | 22 | $367 | $17 |
| Atorvastatin | 74 | $326 | $4 |
| Amlodipine Besylate | 71 | $307 | $4 |
| Diclofenac | 11 | $293 | $27 |
| Pravastatin | 29 | $292 | $10 |
| Metformin | 32 | $206 | $6 |
| Famotidine | 15 | $190 | $13 |
| Losartan | 48 | $160 | $3 |
| Hydroxyzine | 12 | $143 | $12 |
| Trazodone | 15 | $141 | $9 |
| Metformin Hcl Er | 11 | $100 | $9 |
| Lisinopril | 24 | $69 | $3 |
| Omeprazole | 14 | $68 | $5 |
| Hydrochlorothiazide | 16 | $62 | $4 |
| Fluoxetine | 11 | $52 | $5 |
Year by year
| 2024 | 1,019 | 169 | 1% (12) | 13% | $109,939 |
| 2023 | 856 | 128 | None | 16% | $215,480 |
| 2022 | 621 | 96 | None | 15% | $126,363 |
| 2021 | 512 | 92 | None | 15% | $90,640 |
| 2020 | 590 | 112 | None | 15% | $82,453 |
| 2019 | 587 | 99 | None | None | $65,695 |
| 2018 | 663 | 88 | 3% (17) | 18% | $102,818 |
| 2017 | 592 | 108 | 7% (43) | 15% | $60,905 |
| 2016 | 811 | 151 | 4% (35) | 19% | $63,345 |
| 2015 | 1,305 | 105 | 2% (25) | 22% | $115,178 |
| 2014 | 1,328 | 112 | 2% (31) | 22% | $90,251 |
| 2013 | 784 | 84 | 4% (33) | 22% | $50,528 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Novolog Flexpen | 15 | $78,146 | $5,210 |
| Ozempic | 15 | $26,240 | $1,749 |
| Tresiba Flextouch U-200 | 17 | $16,800 | $988 |
| Alendronate | 14 | $1,613 | $115 |
| Rosuvastatin | 28 | $828 | $30 |
| Gabapentin | 27 | $803 | $30 |
| Atorvastatin | 55 | $708 | $13 |
| Levothyroxine | 35 | $556 | $16 |
| Amlodipine Besylate | 57 | $485 | $9 |
| Trazodone | 21 | $416 | $20 |
| Pravastatin | 25 | $403 | $16 |
| Metformin | 32 | $368 | $11 |
| Famotidine | 14 | $331 | $24 |
| Losartan | 27 | $302 | $11 |
| Tamsulosin | 13 | $296 | $23 |
| Lisinopril | 12 | $264 | $22 |
| Hydrochlorothiazide | 17 | $178 | $10 |
| Furosemide | 12 | $47 | $4 |
2022: 15 drugs
| Novolog Flexpen | 13 | $65,592 | $5,046 |
| Tresiba Flextouch U-200 | 23 | $14,954 | $650 |
| Basaglar Kwikpen U-100 | 13 | $5,419 | $417 |
| Buprenorphine-Naloxone | 12 | $955 | $80 |
| Levothyroxine | 31 | $551 | $18 |
| Atorvastatin | 41 | $487 | $12 |
| Pravastatin | 30 | $410 | $14 |
| Gabapentin | 17 | $305 | $18 |
| Trazodone | 16 | $291 | $18 |
| Amlodipine Besylate | 38 | $250 | $7 |
| Losartan | 25 | $235 | $9 |
| Rosuvastatin | 13 | $233 | $18 |
| Alendronate | 16 | $143 | $9 |
| Metformin | 18 | $124 | $7 |
| Hydrochlorothiazide | 12 | $123 | $10 |
2021: 13 drugs
| Tresiba Flextouch U-200 | 14 | $9,025 | $645 |
| Basaglar Kwikpen U-100 | 12 | $7,571 | $631 |
| Levothyroxine | 33 | $831 | $25 |
| Trazodone | 20 | $711 | $36 |
| Pravastatin | 25 | $491 | $20 |
| Rosuvastatin | 15 | $486 | $32 |
| Atorvastatin | 32 | $459 | $14 |
| Gabapentin | 28 | $434 | $16 |
| Amlodipine Besylate | 34 | $243 | $7 |
| Metformin | 13 | $239 | $18 |
| Losartan | 13 | $205 | $16 |
| Alendronate | 11 | $74 | $7 |
| Lisinopril | 13 | $64 | $5 |
2020: 14 drugs
| Tresiba Flextouch U-200 | 22 | $14,185 | $645 |
| Lantus Solostar | 12 | $998 | $83 |
| Atorvastatin | 52 | $735 | $14 |
| Levothyroxine | 24 | $654 | $27 |
| Gabapentin | 30 | $546 | $18 |
| Trazodone | 25 | $512 | $20 |
| Pravastatin | 23 | $376 | $16 |
| Duloxetine | 11 | $212 | $19 |
| Amlodipine Besylate | 30 | $177 | $6 |
| Metformin | 14 | $176 | $13 |
| Metformin Hcl Er | 13 | $139 | $11 |
| Lisinopril | 23 | $137 | $6 |
| Simvastatin | 20 | $128 | $6 |
| Hydrochlorothiazide | 15 | $79 | $5 |
2019: 17 drugs
| Tresiba Flextouch U-200 | 11 | $7,052 | $641 |
| Atorvastatin | 39 | $595 | $15 |
| Pravastatin | 21 | $464 | $22 |
| Gabapentin | 22 | $429 | $19 |
| Levothyroxine | 15 | $402 | $27 |
| Rosuvastatin | 13 | $283 | $22 |
| Amlodipine Besylate | 36 | $244 | $7 |
| Trazodone | 17 | $233 | $14 |
| Amitriptyline | 15 | $224 | $15 |
| Tamsulosin | 13 | $175 | $13 |
| Metformin | 15 | $166 | $11 |
| Lisinopril | 24 | $164 | $7 |
| Atenolol | 13 | $157 | $12 |
| Losartan | 15 | $132 | $9 |
| Metformin Hcl Er | 11 | $130 | $12 |
| Simvastatin | 19 | $119 | $6 |
| Hydrochlorothiazide | 11 | $99 | $9 |
2018: 18 drugs
| Genvoya | 12 | $34,897 | $2,908 |
| Lantus Solostar | 11 | $10,118 | $920 |
| Ultra-Fine Nano Pen Needle | 13 | $979 | $75 |
| Atorvastatin | 57 | $651 | $11 |
| Levothyroxine | 32 | $618 | $19 |
| Amlodipine Besylate | 41 | $589 | $14 |
| Pravastatin | 21 | $525 | $25 |
| Gabapentin | 25 | $390 | $16 |
| Amitriptyline | 14 | $329 | $23 |
| Trazodone | 20 | $258 | $13 |
| Metoprolol | 11 | $218 | $20 |
| Metformin | 23 | $182 | $8 |
| Triamcinolone Acetonide | 11 | $167 | $15 |
| Losartan | 28 | $138 | $5 |
| Simvastatin | 15 | $121 | $8 |
| Lisinopril | 15 | $106 | $7 |
| Alendronate | 11 | $85 | $8 |
| Citalopram Hbr | 11 | $38 | $3 |
2017: 13 drugs
| Oxycodone-Acetaminophen | 11 | $614 | $56 |
| Atorvastatin | 45 | $531 | $12 |
| Hydrocodone-Acetaminophen | 19 | $368 | $19 |
| Gabapentin | 23 | $325 | $14 |
| Pravastatin | 12 | $245 | $20 |
| Amlodipine Besylate | 22 | $221 | $10 |
| Metformin | 22 | $197 | $9 |
| Alendronate | 20 | $140 | $7 |
| Fluticasone Propionate | 13 | $119 | $9 |
| Lisinopril | 35 | $115 | $3 |
| Tamsulosin | 14 | $97 | $7 |
| Clopidogrel | 12 | $53 | $4 |
| Hydrochlorothiazide | 11 | $29 | $3 |
2016: 24 drugs
| Advair Diskus | 18 | $8,108 | $450 |
| Pravastatin | 33 | $1,212 | $37 |
| Ventolin Hfa | 20 | $1,200 | $60 |
| Bd Ultra-Fine Pen Needle | 19 | $761 | $40 |
| Atorvastatin | 25 | $579 | $23 |
| Levothyroxine | 19 | $449 | $24 |
| Tamsulosin | 12 | $432 | $36 |
| Gabapentin | 33 | $363 | $11 |
| Amlodipine Besylate | 64 | $354 | $6 |
| Baclofen | 13 | $337 | $26 |
| Metformin | 29 | $213 | $7 |
| Fluticasone Propionate | 17 | $200 | $12 |
| Famotidine | 21 | $193 | $9 |
| Fosinopril | 14 | $184 | $13 |
| Benazepril | 16 | $148 | $9 |
| Hydrocodone-Acetaminophen | 12 | $139 | $12 |
| Hydrochlorothiazide | 19 | $134 | $7 |
| Lisinopril | 17 | $95 | $6 |
| Losartan | 13 | $86 | $7 |
| Triamcinolone Acetonide | 12 | $79 | $7 |
| Simvastatin | 21 | $77 | $4 |
| Metoprolol | 12 | $76 | $6 |
| Trazodone | 12 | $55 | $5 |
| Furosemide | 12 | $30 | $3 |
2015: 32 drugs
| Lantus Solostar | 23 | $11,046 | $480 |
| Humalog | 13 | $8,574 | $660 |
| Advair Diskus | 19 | $6,429 | $338 |
| Spiriva | 14 | $4,420 | $316 |
| Novolin 70-30 | 14 | $4,098 | $293 |
| Zostavax | 11 | $1,847 | $168 |
| Atorvastatin | 61 | $1,732 | $28 |
| Bd Ultra-Fine Pen Needle | 40 | $1,729 | $43 |
| Pravastatin | 24 | $1,545 | $64 |
| Levothyroxine | 46 | $1,478 | $32 |
| Gabapentin | 59 | $1,280 | $22 |
| Proair Hfa | 20 | $1,150 | $57 |
| Doxazosin Mesylate | 11 | $945 | $86 |
| Amlodipine Besylate | 124 | $914 | $7 |
| Ventolin Hfa | 16 | $879 | $55 |
| Metoprolol | 18 | $781 | $43 |
| Fosinopril | 25 | $601 | $24 |
| Alendronate | 55 | $517 | $9 |
| Famotidine | 42 | $423 | $10 |
| Fluticasone Propionate | 36 | $411 | $11 |
| Metformin | 31 | $325 | $10 |
| Atenolol | 34 | $325 | $10 |
| Baclofen | 13 | $266 | $20 |
| Losartan | 34 | $265 | $8 |
| Oxybutynin Chloride | 12 | $260 | $22 |
| Glipizide | 27 | $258 | $10 |
| Hydrochlorothiazide | 38 | $248 | $7 |
| Benazepril | 17 | $234 | $14 |
| Metoprolol | 22 | $151 | $7 |
| Hydrocodone-Acetaminophen | 13 | $145 | $11 |
| Lisinopril | 15 | $141 | $9 |
| Simvastatin | 30 | $136 | $5 |
2014: 33 drugs
| Advair Diskus | 20 | $6,449 | $322 |
| Humalog | 13 | $5,872 | $452 |
| Lantus | 12 | $4,608 | $384 |
| Lantus Solostar | 11 | $4,602 | $418 |
| Novolin 70-30 | 21 | $4,474 | $213 |
| Pravastatin | 27 | $1,542 | $57 |
| Metoprolol | 27 | $1,451 | $54 |
| Proair Hfa | 18 | $1,429 | $79 |
| Levothyroxine | 54 | $1,278 | $24 |
| Atorvastatin | 46 | $1,269 | $28 |
| Fosinopril | 45 | $1,020 | $23 |
| Amlodipine Besylate | 136 | $966 | $7 |
| Alendronate | 55 | $625 | $11 |
| Ventolin Hfa | 11 | $582 | $53 |
| Famotidine | 43 | $541 | $13 |
| Gabapentin | 42 | $512 | $12 |
| Omeprazole | 19 | $413 | $22 |
| Atenolol | 52 | $394 | $8 |
| Glipizide | 29 | $350 | $12 |
| Metformin | 32 | $343 | $11 |
| Losartan | 20 | $336 | $17 |
| Hydrochlorothiazide | 52 | $327 | $6 |
| Insulin | 13 | $316 | $24 |
| Simvastatin | 34 | $306 | $9 |
| Baclofen | 17 | $275 | $16 |
| Lisinopril | 16 | $244 | $15 |
| Benazepril | 19 | $218 | $11 |
| Hydrocodone-Acetaminophen | 16 | $198 | $12 |
| Metoprolol | 16 | $156 | $10 |
| Naproxen | 16 | $108 | $7 |
| Acetaminophen-Codeine | 14 | $80 | $6 |
| Trazodone | 13 | $57 | $4 |
| Furosemide | 12 | $50 | $4 |
2013: 20 drugs
| Zostavax | 16 | $2,500 | $156 |
| Metoprolol | 15 | $1,091 | $73 |
| Pravastatin | 22 | $915 | $42 |
| Colcrys | 11 | $879 | $80 |
| Atorvastatin | 17 | $782 | $46 |
| Amlodipine Besylate | 55 | $680 | $12 |
| Levothyroxine | 41 | $621 | $15 |
| Alendronate | 33 | $500 | $15 |
| Losartan | 12 | $492 | $41 |
| Fosinopril | 22 | $458 | $21 |
| Atenolol | 49 | $437 | $9 |
| Metformin | 41 | $424 | $10 |
| Famotidine | 23 | $349 | $15 |
| Simvastatin | 30 | $321 | $11 |
| Hydrocodone-Acetaminophen | 24 | $281 | $12 |
| Glipizide | 21 | $248 | $12 |
| Benazepril | 17 | $231 | $14 |
| Gabapentin | 16 | $194 | $12 |
| Hydrochlorothiazide | 33 | $152 | $5 |
| Metoprolol | 11 | $89 | $8 |
Professional record
- NPI
- 1891923686
- Licence
- CA A104342California A104342: Current · expires 2027-09-30
- Trained
- University of California, San Francisco School of Medicine, 2006
- Group
- University Healthcare Alliance · Indian Health Center of Santa Clara Valley
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 330 N Mathilda Ave, #408, Sunnyvale, CA, 94085
- NPI first listed
- 2009-06-30
- NPI last updated
- 2009-06-30
This is when the NPI record was last certified, not a medical board exam.